United States: Capitol Hill Healthcare Update – January 9, 2018


With less than two weeks before another deadline to avert a government shutdown, Republican leaders on Capitol Hill say they're cautiously optimistic about crafting a budget agreement that also would include several key healthcare provisions.

The budget outline would include setting top-line budget numbers for two fiscal years, a long-term reauthorization of the Children's Health Insurance Program (CHIP), renewal of Medicare payment provisions and a series of changes to Affordable Care Act (ACA) provider taxes. While that framework has been discussed among Republicans and Democrats, congressional staff warn it has not been agreed to and could stall over a number of unrelated issues. For example, some Democrats say they will withhold support for a budget agreement or another stopgap spending bill to keep the government open unless their demands for immigration provisions are met.

Passage of a CHIP renewal should be easier after an estimate last week by the Congressional Budget Office found that a five-year renewal would cost only $800 million, down from earlier estimates of $8.2 billion. CBO said the new forecast comes after Congress approved separate tax legislation last month that repealed the ACA's individual mandate, which the agency found would reduce the government's overall healthcare spending.

Dozens of children's hospital executives are in Washington this week, and they are stepping up criticism of Congress for failing to renew the bipartisan program, which expired last September. They are expected to press lawmakers to vote immediately on a five-year renewal.

Under the tentative budget framework, the ACA taxes that could be targeted for a suspension or even repeal include the medical device tax, the tax on insurers and the so-called Cadillac tax on high-cost health plans. But there's disagreement among congressional Republicans on whether to include the ACA tax provisions now or later in a separate tax-only bill.


The Senate Finance Committee on Tuesday will hold a confirmation hearing on Alex Azar, whom President Donald Trump in November nominated for Health & Human Services (HHS) secretary.

Azar enjoys widespread support among Senate Republicans and is likely to be confirmed. But Democrats on the committee are expected to grill Azar over what they say has been Trump's inaction on prescription drug prices and Azar's role in boosting prices while he was a senior executive at Eli Lilly.

Democrats who are likely to pose the sharpest questions to Azar will be the top committee Democrat, Sen. Ron Wyden, D-Ore., as well as Sens. Bill Nelson, D-Fla., Sherrod Brown, D-Ohio, and Claire McCaskill, D-Mo.

Sen. Chuck Grassley, R-Iowa, is a frequent pharma critic, and he is expected to push Azar on prescription drug importation and on manufacturers that use patent laws to extend drug exclusivity. Grassley last year called on HHS to fast-track the importation of prescription drugs from Canada.

Committee Chairman Orrin Hatch is expected to quickly move for a vote by the full committee, and GOP leaders want to get Azar confirmed by the Senate this month.


Congressional Republicans and President Donald Trump met at Camp David over the weekend to plot their 2018 legislative agenda with House GOP leaders, making the case that a Medicaid overhaul tied to welfare reform would help the party's political fortunes in this year's midterm elections.

House Speaker Paul Ryan has long said he wants to focus on entitlement reforms this year, even using budget reconciliation legislation to force a party-line vote and bypass a Democratic-led filibuster in the Senate. But after failing twice last year to repeal the Affordable Care Act (ACA), Senate Republicans are cool to the idea of tackling even Medicaid reform. Senate Majority Leader Mitch McConnell said a Medicaid overhaul could be approved only with support from Democrats, who oppose GOP efforts to block-grant the program.

Although there isn't a clear path for Republicans to enact broad Medicaid reforms this year, House Republicans are not giving up. Even with McConnell signaling the Senate won't pass a Medicaid bill, the House is expected to draft and vote on a Medicaid reform package. House leaders say Medicaid and welfare reform not only align with conservatives' political outlook but also would boost Republicans as they battle to retain their House majority.

Sen. Lindsay Graham, R-S.C., one of the authors of last year's failed ACA repeal bill, said he will press for a new vote this year on his legislation with Sen. Bill Cassidy, R-La., that among other things would transform Medicaid into a block-grant program. But it's not clear Republicans are any closer to gaining the 50 votes they need. The GOP faces a slimmer majority after losing the Alabama special election in December, and two GOP lawmakers – Sens. John McCain, R-Ariz., and Thad Cochran, R-Miss. – have missed votes in recent months due to illnesses.


The Senate last week approved bipartisan legislation that would expand veterans' access to telehealth services, including mental health treatment.

The bill by Sens. Joni Ernst, R-Iowa, and Mazie Hirono, D-Hawaii, is similar to legislation that won House approval last year.

The Senate bill targets disabled and rural veterans by expanding telehealth services to allow Department of Veterans Affairs' (VA) officials to practice telemedicine across state lines. It also calls on the VA to study the effectiveness of telehealth services with the hope it could be expanded to cover other treatment areas.


The Senate last year approved legislation that would give terminally ill patients wider access to prescription drugs that haven't yet won Food and Drug Administration (FDA) approval, and now a conservative political advocacy group is calling on Republican leaders to schedule a vote in the House.

Americans for Prosperity, which is funded by Republican activist brothers David Koch and Charles Koch, wants House Energy and Commerce Committee Chairman Greg Walden, R-Ore., to schedule a vote on a House version of the bill. In a letter to Walden, the group said the FDA's compassionate use program, which allows terminally ill patients to access experimental drugs, is "costly, onerous and overly complicated."

Vice President Michael Pence last year endorsed the so-called right-to-try legislation backed by Sen. Ron Johnson, R-Wis. Pharmaceutical manufacturers have resisted the bill, saying early access to unapproved drugs could give patients false hope and threatens the integrity of ongoing clinical trials if those patients have adverse reactions.


A group of conservative policy and political activists is calling on congressional Republicans to vote again on repealing the Affordable Care Act (ACA).

The group includes think tanks Heritage Action, the Hoover Institution and the American Enterprise Institute, as well as former Sen. Rick Santorum, R-Pa.

"Health costs are rising faster than before [the ACA], and there's no real prospect of a reversal without legislative action," the group wrote in a letter to Republican congressional leaders.

While a new push to repeal the ACA is unlikely in Congress, the letter reflects political pressure congressional Republicans continue to feel from conservative grassroots activists, who will play a key role in contested House and Senate Republican primary elections that begin next month.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Similar Articles
Relevancy Powered by MondaqAI
In association with
Related Topics
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.


The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.


Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions